Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
6.82
USD
|
+1.04%
|
|
+2.40%
|
+12.36%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
646.3
|
674.7
|
715.5
|
301.4
|
1,861
|
2,105
|
-
|
-
|
Enterprise Value (EV)
1 |
3,187
|
3,210
|
3,169
|
2,888
|
4,182
|
4,454
|
4,230
|
3,962
|
P/E ratio
|
-1.76
x
|
7.49
x
|
68.4
x
|
-2.31
x
|
-12.6
x
|
-25.3
x
|
97.4
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
0.44%
|
-
|
-
|
Capitalization / Revenue
|
0.4
x
|
0.34
x
|
0.34
x
|
0.14
x
|
0.78
x
|
0.79
x
|
0.75
x
|
0.73
x
|
EV / Revenue
|
1.96
x
|
1.61
x
|
1.51
x
|
1.31
x
|
1.75
x
|
1.67
x
|
1.52
x
|
1.37
x
|
EV / EBITDA
|
8.96
x
|
7.04
x
|
5.89
x
|
5.62
x
|
7.49
x
|
7.29
x
|
6.7
x
|
6.04
x
|
EV / FCF
|
-70.1
x
|
9.95
x
|
16.3
x
|
155
x
|
13.8
x
|
16.9
x
|
13.9
x
|
10.7
x
|
FCF Yield
|
-1.43%
|
10%
|
6.12%
|
0.65%
|
7.23%
|
5.93%
|
7.19%
|
9.31%
|
Price to Book
|
6.22
x
|
4.52
x
|
4.01
x
|
2.02
x
|
54.1
x
|
-85.3
x
|
35.9
x
|
-
|
Nbr of stocks (in thousands)
|
134,096
|
147,628
|
149,371
|
151,476
|
306,544
|
308,651
|
-
|
-
|
Reference price
2 |
4.820
|
4.570
|
4.790
|
1.990
|
6.070
|
6.820
|
6.820
|
6.820
|
Announcement Date
|
2/26/20
|
2/26/21
|
3/1/22
|
3/2/23
|
3/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,626
|
1,993
|
2,094
|
2,212
|
2,394
|
2,666
|
2,790
|
2,890
|
EBITDA
1 |
355.5
|
456.2
|
538.1
|
514.1
|
558.2
|
611.1
|
631.2
|
656.2
|
EBIT
1 |
292.2
|
325.6
|
387.9
|
343.3
|
379.1
|
551.9
|
556.6
|
570.9
|
Operating Margin
|
17.97%
|
16.34%
|
18.53%
|
15.52%
|
15.84%
|
20.7%
|
19.95%
|
19.75%
|
Earnings before Tax (EBT)
1 |
-220.2
|
-35.78
|
-
|
-
|
-40.72
|
-58.29
|
73.45
|
-
|
Net income
1 |
-603.6
|
68.58
|
20.17
|
-
|
-83.99
|
-84.18
|
23.06
|
-
|
Net margin
|
-37.11%
|
3.44%
|
0.96%
|
-
|
-3.51%
|
-3.16%
|
0.83%
|
-
|
EPS
2 |
-2.740
|
0.6100
|
0.0700
|
-0.8600
|
-0.4800
|
-0.2700
|
0.0700
|
-
|
Free Cash Flow
1 |
-45.48
|
322.6
|
194.1
|
18.69
|
302.4
|
264.2
|
304.2
|
369
|
FCF margin
|
-2.8%
|
16.19%
|
9.27%
|
0.84%
|
12.63%
|
9.91%
|
10.9%
|
12.77%
|
FCF Conversion (EBITDA)
|
-
|
70.71%
|
36.07%
|
3.64%
|
54.17%
|
43.23%
|
48.19%
|
56.24%
|
FCF Conversion (Net income)
|
-
|
470.35%
|
962.28%
|
-
|
-
|
-
|
1,318.8%
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
0.0300
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/26/21
|
3/1/22
|
3/2/23
|
3/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
536.9
|
497.6
|
559.4
|
545.6
|
609.8
|
557.5
|
599
|
620
|
617
|
659.2
|
664.4
|
666.3
|
676.1
|
682.4
|
690
|
EBITDA
1 |
126.4
|
99.86
|
134.6
|
125.6
|
154
|
116.2
|
146.1
|
153.8
|
142.1
|
152.4
|
144.4
|
148.5
|
151
|
150.9
|
151
|
EBIT
1 |
77.96
|
81.31
|
119.4
|
106.8
|
105.3
|
128.7
|
124.3
|
131.9
|
92.98
|
169.3
|
136.6
|
139.5
|
139.9
|
130.3
|
141.3
|
Operating Margin
|
14.52%
|
16.34%
|
21.35%
|
19.58%
|
17.27%
|
23.09%
|
20.76%
|
21.28%
|
15.07%
|
25.69%
|
20.56%
|
20.94%
|
20.69%
|
19.1%
|
20.48%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
22.96
|
-83.46
|
-75.52
|
4.346
|
5.555
|
7.326
|
15.06
|
15.56
|
Net income
1 |
-20.46
|
-2.156
|
-120.8
|
-
|
-
|
-
|
-
|
9.682
|
-98.65
|
-91.64
|
1.88
|
2.403
|
3.169
|
4.727
|
4.886
|
Net margin
|
-3.81%
|
-0.43%
|
-21.6%
|
-
|
-
|
-
|
-
|
1.56%
|
-15.99%
|
-13.9%
|
0.28%
|
0.36%
|
0.47%
|
0.69%
|
0.71%
|
EPS
2 |
-0.0400
|
-0.0100
|
-0.8000
|
-0.0200
|
-0.0300
|
-0.0500
|
0.0800
|
0.0600
|
-0.4000
|
-0.3000
|
0.0100
|
0.0100
|
0.0100
|
0.0100
|
0.0200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
5/4/22
|
8/5/22
|
11/4/22
|
3/2/23
|
5/5/23
|
8/4/23
|
11/7/23
|
3/1/24
|
5/3/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
2,541
|
2,536
|
2,454
|
2,587
|
2,321
|
2,349
|
2,125
|
1,857
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
7.147
x
|
5.559
x
|
4.561
x
|
5.031
x
|
4.158
x
|
3.844
x
|
3.366
x
|
2.83
x
|
Free Cash Flow
1 |
-45.5
|
323
|
194
|
18.7
|
302
|
264
|
304
|
369
|
ROE (net income / shareholders' equity)
|
28.1%
|
71.4%
|
75.5%
|
75.4%
|
194%
|
153%
|
58.5%
|
38.3%
|
ROA (Net income/ Total Assets)
|
2.58%
|
4.98%
|
6.5%
|
5.37%
|
5.43%
|
5.01%
|
5.16%
|
5.48%
|
Assets
1 |
-23,360
|
1,377
|
310.5
|
-
|
-1,546
|
-1,679
|
447.2
|
-
|
Book Value Per Share
2 |
0.7800
|
1.010
|
1.200
|
0.9800
|
0.1100
|
-0.0800
|
0.1900
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
47.2
|
56.4
|
47.7
|
46.4
|
43.2
|
47.4
|
59.9
|
55
|
Capex / Sales
|
2.9%
|
2.83%
|
2.28%
|
2.1%
|
1.81%
|
1.78%
|
2.15%
|
1.9%
|
Announcement Date
|
2/26/20
|
2/26/21
|
3/1/22
|
3/2/23
|
3/1/24
|
-
|
-
|
-
|
Last Close Price
6.82
USD Average target price
8.25
USD Spread / Average Target +20.97% Consensus |
1st Jan change
|
Capi.
|
---|
| +12.36% | 2.11B | | +32.09% | 693B | | +29.39% | 584B | | -1.34% | 372B | | +20.34% | 332B | | +7.39% | 294B | | +14.25% | 239B | | -3.03% | 211B | | +10.02% | 210B | | +8.49% | 168B |
Other Pharmaceuticals
|